PLUS1
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Iovance Biotherapeutics Inc | IOVA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.19 | -0.84% | 22.43 | 22.76 | 22.068 | 22.43 | 22.62 | 11:16:09 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 22.45 | 22.49 | 0.04 | 0.18% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,847 | 222,871 | $ 22.34 | $ 4,978,795 | 1,161,850 | 7.26 - 26.59 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:16:08 | 1 | $ 22.43 | USD |
Iovance Biotherapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 2.83B | 126.19M | $ -123.58M | -1.27 | - | 105.17M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Iovance Biotherapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/08/2019 | 13:20 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) |
| 11/08/2019 | 07:00 | GlobeNewswire Inc. | Iovance Biotherapeutics Announces Updated Phase 2 Clinical.. |
| 11/07/2019 | 16:32 | GlobeNewswire Inc. | Iovance Biotherapeutics to Present at Upcoming Investor.. |
| 11/04/2019 | 17:03 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 11/04/2019 | 16:13 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/04/2019 | 16:01 | GlobeNewswire Inc. | Iovance Biotherapeutics Reports Third Quarter and September.. |
| 10/31/2019 | 16:43 | GlobeNewswire Inc. | Iovance Biotherapeutics to Host Third Quarter 2019 Financial.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IOVA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 21.42 | 24.50 | 20.45 | 23.03 | 1,564,718 | 1.01 | 4.72% |
| 1 Month | 18.50 | 24.50 | 18.30 | 21.47 | 1,222,995 | 3.93 | 21.24% |
| 3 Months | 20.02 | 24.50 | 17.67 | 20.36 | 1,242,321 | 2.41 | 12.04% |
| 6 Months | 10.25 | 26.59 | 10.25 | 20.13 | 1,652,594 | 12.18 | 118.83% |
| 1 Year | 9.25 | 26.59 | 7.26 | 16.22 | 1,381,295 | 13.18 | 142.49% |
| 3 Years | 7.70 | 26.59 | 4.45 | 14.02 | 929,980 | 14.73 | 191.3% |
| 5 Years | 8.57 | 26.59 | 4.24 | 12.87 | 745,720 | 13.86 | 161.73% |
Iovance Biotherapeutics Description
| Iovance Biotherapeutics Inc operates in the healthcare sector based in the United States. It is a pharmaceutical manufacturer attending to serious diseases such as cancer. The Company's lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma. The TIL therapy involves growing a patient's special culture conditions outside the patient's body, or ex vivo, and then infusing the T cells back into the patient. |
